Loading...
Loading...
- Silk Road Medical Inc SILK posted Q2 revenue of $33.2 million, an increase of 25% Y/Y, driven primarily by increased TCAR adoption, beating the consensus of $31.16 million.
- "We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a $250 million debt facility," said Erica Rogers, CEO
- "We also gained meaningful market share through strong physician utilization as we continue to establish TCAR as the minimally-invasive standard of care in stroke prevention, evidenced by recently eclipsing 50,000 global TCAR procedures," Rogers added.
- Gross margin declined to 73% from 75%, impacted by continued manufacturing expansion costs at the new Minnesota facility.
- EPS loss reached $(0.44) compared to $(0.31) a year ago, beating the consensus of $(0.46).
- Guidance: Silk Road Medical projects FY22 revenue of $128 million - $133 million versus the consensus of $129.32 million.
- Price Action: SILK shares traded 2.13% higher at $44.06 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in